PHOENIX, May 15, 2019 (GLOBE NEWSWIRE) -- Item 9 Labs Corp. (OTC: INLB) (“Item 9 Labs” or the “Company”), a leader in comfortable cannabis health solutions for the modern consumer, today announced CEO Sara Gullickson was selected by Industry Leaders Magazine as one of the top influential businesswomen in the cannabis industry. The magazine provides a global business platform highlighting entrepreneurs and companies driving worldwide economies. The accolade is one of several the well-renowned CEO has received.
Gullickson was recognized for her nine years as a progressive cannabis executive and recent leadership at publicly traded Item 9 Labs. In addition, Gullickson was recently selected by the Phoenix Business Journal to judge their Top 40 Under 40 Award applications. Gullickson received the award in 2018, joining an exclusive club of more than 680 other Top 40 Under 40 alumni.
“I am honored to be recognized on a mainstream level for my work within the cannabis industry,” stated Gullickson. “I want to inspire other women to become leaders in the cannabis space because diversity breeds success.”
Headquartered in Phoenix, Item 9 Labs is bringing best industry practices to markets from coast to coast through cultivation, dispensary, and processing operations, as well as licensing services, and medical cannabis product suites.
In other news, Gullickson shared the Item 9 Labs mission and her vision in a live interview with Follow the Money Investor Group, a financial portal that provides essential content and information to navigate ever changing capital markets. The feature discussed how the Company is advancing the cannabis industry and future expansion plans.
Item 9 Labs currently has distribution and processing operations Strive Wellness of Ohio and Strive Wellness of Nevada, as well as dispensary Strive Life North Dakota. The Company intends to manage facilities in six to ten U.S. cannabis markets by the end of 2019.
For information visit Item9LabsCorp.com.
About Item 9 Labs Corp.:
Item 9 Labs Corp. (OTC: INLB) creates comfortable cannabis health solutions for the modern consumer. The Company is bringing best of industry practices to markets from coast to coast through cultivation and production, distinctive retail environments, licensing services, and diverse product suites catering to different medical cannabis demographics. Item 9 Labs Corp. is headquartered in Phoenix, Arizona, with medical cannabis operations in multiple U.S. markets.
Item 9 Labs Corp.’s asset portfolio includes Dispensary Permits, Dispensary Templates, and Strive Life. These assets provide services specific to different stakeholder groups. Dispensary Permits is the Company’s consulting firm specializing in strategic license application and compliance. Dispensary Templates, a subdivision of the firm, is a technology platform with an extensive digital library of licensing and business planning resources. Strive Life is a turnkey dispensary model for the retail sector, elevating the patient experience with consistent and superior service, high-end design, and precision-tested products. It is currently being implemented in Arizona and North Dakota.
In addition, Item 9 Labs Corp. is advancing the industry with its dynamic product suites. The Company has created complementary brands Item 9 Labs and Strive Wellness to channel consumer diversity. Propriety delivery platforms include the Apollo Vape and Pod system, as well as a pioneering intra-nasal device. The Company has received multiple accolades for its medical-grade flower and concentrates.
Item 9 Labs Corp. intends to manage cultivation, processing, distribution, and dispensary operations in up to ten U.S. markets by the end of 2019. Current facilities include distribution and processing operations Strive Wellness of Ohio and Strive Wellness of Nevada, as well as dispensary Strive Life North Dakota.
For more information, visit Item 9 Labs Corp. at www.Item9labscorp.com.
Forward-Looking Statement: This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties, including, but not limited to, risks and effects of legal and administrative proceedings and governmental regulation, especially in a foreign country, future financial and operational results, competition, general economic conditions, proposed transactions that are not legally binding obligations of the company and the ability to manage and continue growth. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual outcomes may vary materially from those indicated. Important factors that could cause actual results to differ materially from the forward-looking statements we make in this news release include the introduction of new technology, market conditions and those set forth in reports or documents we file from time to time with the SEC. We undertake no obligation to revise or update such statements to reflect current events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
Media Contact:
Neko Catanzaro
Proven Media
Neko@provenmediaservices.com
(401) 484-4980
Investor Contact:
Jeffrey Rassás
Item 9 Labs Corp.
Jeffrey@item9labs.com
(602) 463-4246
A video accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/b79b1f2c-3fb4-4d4c-97fc-b710389624ef